View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 25, 2020

Dexamethasone, an unexpected drug, shows promise in treating Covid-19

By GlobalData Healthcare

Currently, there are over 2,200 clinical trials trying to find a vaccine or a therapy for Covid-19. The National Institute of Health recently halted its hydroxychloroquine clinical trial, concluding that there was no real benefit for Covid-19 patients. On the other hand, dexamethasone has recently shown positive preliminary results from the RECOVERY (Randomised Evaluation of COVid-19 thERapY) clinical trial.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The UK RECOVERY trial is a Phase II/III randomised, controlled trial that began in March 2020 and is testing numerous potential treatments for Covid-19, including lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, and low-dose dexamethasone. The trial also had a hydroxychloroquine arm, but the UK Medicines and Healthcare Products Regulatory Agency (MHRA) suspended this due to no significant difference in mortality rate and hospital stay duration. More than 11,000 patients were enrolled in 175 NHS hospitals in the UK. A total of 2,104 patients were randomised to receive 6mg per day of dexamethasone for 10 days and then compared to 4,321 patients that received usual care alone (patients on ventilation, patients who required oxygen only, and those who did not need any respiratory assistance). Dexamethasone was found to reduce deaths in patients on ventilators by one-third and by one-fifth in patients who required oxygen only. No benefits were found in those who did not need respiratory assistance. With these results, the UK government approved the use of dexamethasone for Covid-19 patients needing oxygen and those on ventilators.

Although these early preliminary results are very promising, only the complete results will provide a full picture and robust assessment. With 14 additional clinical trials investigating dexamethasone against Covid-19 and with eight trials expected to complete in 2020, this could provide additional evidence for the efficacy of dexamethasone for the treatment of Covid-19.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena